Literature DB >> 17404338

A lesson learnt: the rise and fall of Lariam and Halfan.

Ashley M Croft1.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17404338      PMCID： PMC1847738          DOI： 10.1177/014107680710011411

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   5.344


× No keyword cloud information.
  39 in total

1.  Does mefloquine prophylaxis affect electroencephalographic patterns?

Authors:  Israel Potasman; Yoav Juven; Boaz Weller; Eli Schwartz
Journal:  Am J Med       Date:  2002-02-01       Impact factor: 4.965

2.  Sudden death in a traveler following halofantrine administration--Togo, 2000.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2001-03-09       Impact factor: 17.586

3.  Fatal cardiac incident after use of halofantrine.

Authors:  D Malvy; M C Receveur; P Ozon; F Djossou; P Le Metayer; J E Touze; M Longy-Boursier; M Le Bras
Journal:  J Travel Med       Date:  2000 Jul-Aug       Impact factor: 8.490

4.  FDA requires warnings on anti-malaria drug Lariam.

Authors: 
Journal:  Consum Rep       Date:  2004-01

5.  Severe cardiac toxicity due to halofantrine: importance of underlying heart disease.

Authors:  Olivier Bouchaud; Fabrice Bruneel; Ricarda Schiemann; Gilles Peytavin; Jean P Coulaud
Journal:  J Travel Med       Date:  2002 Jul-Aug       Impact factor: 8.490

6.  Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study.

Authors:  D Overbosch; H Schilthuis; U Bienzle; R H Behrens; K C Kain; P D Clarke; S Toovey; J Knobloch; H D Nothdurft; D Shaw; N S Roskell; J D Chulay
Journal:  Clin Infect Dis       Date:  2001-09-05       Impact factor: 9.079

Review 7.  Mefloquine for preventing malaria in non-immune adult travellers.

Authors:  A M Croft; P Garner
Journal:  Cochrane Database Syst Rev       Date:  2000

8.  Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study.

Authors:  Patricia Schlagenhauf; Alois Tschopp; Richard Johnson; Hans D Nothdurft; Bernhard Beck; Eli Schwartz; Markus Herold; Bjarne Krebs; Olivia Veit; Regina Allwinn; Robert Steffen
Journal:  BMJ       Date:  2003-11-08

Review 9.  Safety evaluation of the drugs available to prevent malaria.

Authors:  Ashley M Croft; Dominic P Whitehouse; Gordon C Cook; M Dominic Beer
Journal:  Expert Opin Drug Saf       Date:  2002-05       Impact factor: 4.250

10.  Adverse effects of the antimalaria drug, mefloquine: due to primary liver damage with secondary thyroid involvement?

Authors:  Ashley M Croft; Andrew Herxheimer
Journal:  BMC Public Health       Date:  2002-03-25       Impact factor: 3.295
View more
  18 in total

1.  Lariam and Halfan.

Authors:  John Black
Journal:  J R Soc Med       Date:  2007-08       Impact factor: 5.344

2.  Case Study of Small Molecules As Antimalarials: 2-Amino-1-phenylethanol (APE) Derivatives.

Authors:  María J Chaparro; Jaume Vidal; Iñigo Angulo-Barturen; José M Bueno; Jeremy Burrows; Nicholas Cammack; Pablo Castañeda; Gonzalo Colmenarejo; José M Coterón; Laura de Las Heras; Esther Fernández; Santiago Ferrer; Raquel Gabarró; Francisco J Gamo; Mercedes García; María B Jiménez-Díaz; María J Lafuente; María L León; María S Martínez; Douglas Minick; Sara Prats; Margarita Puente; Lourdes Rueda; Elena Sandoval; Angel Santos-Villarejo; Michael Witty; Félix Calderón
Journal:  ACS Med Chem Lett       Date:  2014-03-26       Impact factor: 4.345

3.  Derivatives of the Antimalarial Drug Mefloquine Are Broad-Spectrum Antifungal Molecules with Activity against Drug-Resistant Clinical Isolates.

Authors:  Marhiah C Montoya; Sarah Beattie; Kathryn M Alden; Damian J Krysan
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

4.  Antimalarial Natural Products.

Authors:  David G I Kingston; Maria Belen Cassera
Journal:  Prog Chem Org Nat Prod       Date:  2022

5.  Synthesis and initial evaluation of quinoline-based inhibitors of the SH2-containing inositol 5'-phosphatase (SHIP).

Authors:  Christopher M Russo; Arijit A Adhikari; Daniel R Wallach; Sandra Fernandes; Amanda N Balch; William G Kerr; John D Chisholm
Journal:  Bioorg Med Chem Lett       Date:  2015-09-15       Impact factor: 2.823

6.  Expanding the Antimalarial Drug Arsenal-Now, But How?

Authors:  Brian T Grimberg; Rajeev K Mehlotra
Journal:  Pharmaceuticals (Basel)       Date:  2011-05-01

7.  Mefloquine use, psychosis, and violence: a retinoid toxicity hypothesis.

Authors:  Anthony Mawson
Journal:  Med Sci Monit       Date:  2013-07-15

8.  Idiosyncratic quinoline central nervous system toxicity: Historical insights into the chronic neurological sequelae of mefloquine.

Authors:  Remington L Nevin
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2014-04-05       Impact factor: 4.077

Review 9.  Targeting SHIP1 and SHIP2 in Cancer.

Authors:  Chiara Pedicone; Shea T Meyer; John D Chisholm; William G Kerr
Journal:  Cancers (Basel)       Date:  2021-02-20       Impact factor: 6.639

10.  Economic evaluation of an alternative drug to sulfadoxine-pyrimethamine as intermittent preventive treatment of malaria in pregnancy.

Authors:  Elisa Sicuri; Silke Fernandes; Eusebio Macete; Raquel González; Ghyslain Mombo-Ngoma; Achille Massougbodgi; Salim Abdulla; August Kuwawenaruwa; Abraham Katana; Meghna Desai; Michel Cot; Michael Ramharter; Peter Kremsner; Laurence Slustker; John Aponte; Kara Hanson; Clara Menéndez
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.